




20

Patent Docket P1747R2D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Garovoy et al. Serial No.: 10/655,905 Filed: September 5, 2003 For: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES OF LFA-1 ANTAGONIST	Group Art Unit: 1644 Examiner: not yet assigned Confirmation No: 7684 Customer No: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 9, 2004  Ann Savelli
--	--

REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:


The "Title" should read as follows:

--Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist--

The above correction is due to applicants' error and the fee therefor under 37 CFR 1.19(h) is applicable. Please charge Deposit Account 07-0630 in the amount of \$25.00 to cover the cost.

Respectfully submitted,
GENENTECH, INC.

Date: January 9, 2004

By: 
Lee K. Tan, Ph.D.
Reg. No. 39,447
Telephone No. (650) 225-4462



UNITED STATES PATENT AND TRADEMARK OFFICE

47/E/CK
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART. 35101 NO.	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/655,905	09/05/2003	344	750	P1747R2D1	10	15	1

09157
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CA 94080

RECEIVED

DEC 09 2003

GENENTECH, INC.
LEGAL, DEPT.

CONFIRMATION NO. 7684

FILING RECEIPT



OC000000011380828

Date Mailed: 12/01/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Marvin R. Garovoy, San Anselmo, CA;
Susan M. Kramer, San Francisco, CA;
Russell L. Dedrick, Kensington, CA;
Karen Starko, Hillsborough, CA;

Assignment For Published Patent Application

Genentech, Inc., South San Francisco, CA;
Xoma Ltd., Berkeley, CA;

Domestic Priority data as claimed by applicant

This application is a DIV of 09/936,603 02/11/2002 PAT 6,652,855
which is a 371 of PCT/US00/07189 03/17/2000
which claims benefit of 60/125,351 03/19/1999
and claims benefit of 60/125,228 03/19/1999

Foreign Applications

If Required, Foreign Filing License Granted: 11/28/2003

Projected Publication Date: 03/11/2004

Non-Publication Request: No

Early Publication Request: No



Title

Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist.

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).